PharmTech Drug Digest 11.20
|Articles|July 17, 2015

PDA Education Course: Establishment of a Risk Based Environmental Monitoring Program

This podcast will feature the instructor of PDA’s new Education course, Establishment of a Risk-Based Environmental Monitoring Program, to be offered September 11, 2015 at PDA’s Training and Research Institute, located in Bethesda, MD. This course will present information on the establishment of a risk based environmental monitoring (EM) program, covering both the establishment of new EM programs as well as reassessment of current EM programs to ensure they are in compliance with industry standards. The goal is for participants to understand the tools available for conducting EM risk assessments and how to properly use them to create risk-based EM programs.

This podcast will feature the instructor of PDA’s new Education course, Establishment of a Risk-Based Environmental Monitoring Program, to be offered September 11, 2015 at PDA’s Training and Research Institute, located in Bethesda, MD.

This course will present information on the establishment of a risk based environmental monitoring (EM) program, covering both the establishment of new EM programs as well as reassessment of current EM programs to ensure they are in compliance with industry standards. The goal is for participants to understand the tools available for conducting EM risk assessments and how to properly use them to create risk-based EM programs.

The course format includes small group breakouts for completion of EM risk assessments.

 


Related to this article

Are Your Supplier Selection and Oversight Processes Robust Enough?
Despite best efforts to ensure a contract organization is following GMPs, a warning letter is issued by the FDA. Susan J. Schniepp, distinguished fellow at Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical at Parexel, provide advice for create a robust supplier selection and oversight system.
white pill capsule isolated on white background | Image Credit: ©F16-ISO100 -stock.adobe.com
PharmTech spoke with Chiara Bergerone, deputy CEO of Roquette’s Health & Pharma Solutions Business, about the company’s hydroxypropyl methylcellulose (HPMC) capsule, which was previewed at CPHI Milan 2026 in October.
Transitioning mRNA from R&D to GMP
Marco Pupo, PhD, innovation and development coordinator at Anemocyte, discusses the R&D-to-GMP transition and the changing shape of mRNA manufacturing facilities.